Huber Capital Management LLC Purchases 22,900 Shares of Kenvue Inc. (NYSE:KVUE)

Huber Capital Management LLC raised its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 15.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 169,300 shares of the company's stock after acquiring an additional 22,900 shares during the period. Huber Capital Management LLC's holdings in Kenvue were worth $3,615,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Kenvue in the 4th quarter valued at about $521,348,000. State Street Corp lifted its holdings in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Finally, Boston Partners raised its position in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after buying an additional 6,366,097 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

NYSE KVUE traded down $1.29 during trading on Friday, hitting $22.33. 17,763,957 shares of the company's stock traded hands, compared to its average volume of 16,812,043. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $42.68 billion, a price-to-earnings ratio of 42.14, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business has a 50 day moving average of $22.59 and a 200-day moving average of $22.46.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Barclays lifted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Thursday, March 27th. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.